

MARKET REPORT



Physician Views: With Januvia data looming, what impact will FDA AdComm have on use of DPP-IV inhibitors?

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Physician Views: With Januvia data looming, what impact will FDA AdComm have on use of DPP-IV inhibitors?

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Physician Views: With Januvia data looming, what impact will FDA AdComm have on use of DPP-IV inhibitors?

Scope

Lingering concerns have been hanging over AstraZeneca's Onglyza and Takeda's Nesina since 2013 when detailed analyses from respective cardiovascular (CV) outcomes studies suggested the DPP-IV inhibitors may be associated with an increased risk of heart failure.

On April 14, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee finally provided some semblance of closure to the matter when it voted overwhelmingly in favour of changing the labels of both drugs to include new warning information about the possible heart failure risk.

Rather than be hurt by the recommendation though, Takeda and (especially) AstraZeneca were able to let out small sighs of relief that the worst case scenario - however improbable - of market withdrawals had been avoided, along with the slightly more possible scenario where use of the drugs would be restricted to certain patients. (See ViewPoints: Handicapping potential outcomes from Tuesday's FDA meeting to discuss safety of DPP-IV inhibitors.)

One wildcard looming over the proceedings is the ongoing CV outcomes study (TECOS) evaluating Merck & Co.'s Januvia, the market-leading DPP-IV inhibitor, which will play a key role in determining whether the heart failure signal is deemed to be a class effect and, more importantly, what impact it will have on use of the three medicines - and each individually.

Waiting in the wings for any possible fallout from the increased scrutiny on DPP-IV inhibitors are agents in classes like the SGLT2 inhibitors, which analysts suggest could gain an increased share of the market should physicians shy away from Januvia, Onglyza and/or Nesina.

Purchase Reasons

To gain better understanding about the impact of the FDA panel's discussion and recommendations, FirstWord PLUS is polling US- and EU5-based endocrinologists and asking them...

Given the increased scrutiny of DPP-IV safety, might you be more likely to reach for another therapeutic modality rather than a DPP-IV inhibitor?Additional Details

Publisher : FirstWord Pharma

Reference :

Number of Pages : 0

Report Format : PDF

Publisher Information :



FirstWord

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

How to Buy...Physician Views: With Januvia data looming, what impact will FDA AdComm have on use of DPP-IV inhibitors?**Option 1 - Online**

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/217>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

\$695 | Single User Price

\$1395 | Global License Price

Payment Options: (please tick one)

Online Credit Card (we will email you the invoice with a payment link)

Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.